The chemotherapy drug docetaxel has been around for decades, but new research shows if used earlier, it can help men with metastatic prostate cancer live much longer – adding 22 months of life ...

OH assessed the molecular and histological changes that occurred in patients with high-risk localized prostate cancer who received neoadjuvant docetaxel chemotherapy before radical prostatectomy.

"Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors ... phase III randomized trial to compare docetaxel plus placebo or pembrolizumab in men with mCRPC ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

randomized phase III trial of pembrolizumab and docetaxel versus placebo and docetaxel in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer, demonstrating that ...

neoadjuvant hormonal therapy can improve tumor control in locally advanced prostate cancer, but studies have shown limited effects on patient survival. The combination of docetaxel chemotherapy ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

It is the first therapeutic cancer vaccine to receive FDA approval ... metastatic CRPC receive sipuleucel-T prior to docetaxel-based chemotherapy 9,10, without it being possible to gauge treatment ...

“We felt that simply making the decision to give chemotherapy would ... in men with castration-resistant prostate cancer who have previously received docetaxel, is currently underway.

The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier ...

Early phase clinical trials have shown that using docetaxel as neoadjuvant ... to identify whether the early use of chemotherapy in early prostate cancer is beneficial. Prostate cancer is the ...